NasdaqCM – Nasdaq Real Time PriceUSD
Retension Pharmaceuticals, Inc. (RTSN)
11.70+0.34(+2.95%)
As of 10:52:13 a.m. EST. Market Open.
Chart Range Bar
Key Events
Advanced Chart
Loading chart for RTSN
- Previous Close
- Open
- Bid14.24 x 100
- Ask13.58 x 100
- Day’s Range
- 52 Week Range
- Volume
- Avg. Volume
- Market Cap (intraday)
- Beta (5Y Monthly)–
- PE Ratio (TTM)
- EPS (TTM)
- Earnings Date–
- Forward Dividend & Yield– (0.00%)
- Ex-Dividend Date–
- 1y Target Est
Retension Pharmaceuticals, Inc. operates as a clinical -stage biopharmaceutical company focused on developing medicines for the treatment of hypertension and other cardiovascular diseases. It offers RTN -001, an oral, small molecule phosphodiesterase -5 inhibitor designed to reduce blood pressure by potentiating nitric oxide signaling. The Company operates as a single operating and reportable segment focused on the development of treatments for hypertension and cardiovascular disease. The company was incorporated in 2023 and is headquartered in Falls Church, Virginia.
Full Time Employees
Fiscal Year Ends
Sector
Industry
Trailing total returns as of 2026-11-02, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
RTSN
16.95%
S&P 500 (^GSPC)
11.55%
RTSN
16.95%
S&P 500 (^GSPC)
11.63%
RTSN
16.95%
S&P 500 (^GSPC)
76.85%
RTSN
16.95%
S&P 500 (^GSPC)
64.90%
Annual
Profitability and Income Statement
-
Net Income Avi to Common (ttm)
Balance Sheet and Cash Flow
TRXB
ETRA
IAM
LTGO
COAG
